Zobrazeno 1 - 10
of 53
pro vyhledávání: ''
Autor:
Jun Gu, Xiaoyu Chen, Wenhua Zhou, Xiaohu Xie, Longhui Li, Huifen Liu, Weisheng Chen, Wenwen Shen, Dingding Zhuang, Yue Liu, Yun Zhou, Wenjin Xu, Qingxiao Hong
Publikováno v:
Personalized Medicine. 18:423-430
Aim: This study determined if gene variants in the GABA receptor delta subunit ( GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction. Materials & methods: A total of 286 MMT patients we
Autor:
Rongrong Zhou, Han Wang, Zhiyuan Liu, Haiqin Peng, Hexin Duan, Jiahui Li, Lei Yang, Xuan Gao, Gang Xiao
Publikováno v:
Immunotherapy. 13:1031-1051
Brain metastases (BM) is common in non-small-cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors (ICIs) have gradually become a routine treatment for NSCLC BM patients. Currently, three PD-1 inhibitors (pembrolizumab, nivolumab and cemipl
Publikováno v:
Immunotherapy. 13:1053-1065
PD-L1 is an important predictive biomarker for treatment by immune checkpoint inhibitors (ICIs). ICIs are now indicated for the treatment of various cancer depending on the level of expression of PD-L1 on tumor cells. PD-L1 testing is done using immu
Autor:
Muhammad Atif Nisar, Adnan Khan, Anam Khalid, Khalid Omer Abdalla Abosalif, Kashaf Junaid, Muhammad Shafique, Muhammad Hidayat Rasool, Atifa Ambreen, Alia Batool, Hasan Ejaz, Muhammad Usman Qamar
Publikováno v:
Future Microbiology. 16:731-739
Aim: To determine the prevalence of multidrug (MDR) and extensively drug-resistant (XDR) pathogens from pediatric blood samples Methods: In total, 4543 children's blood samples were processed in the BacT/ALERT system. Confirmation of the isolates and
Publikováno v:
Personalized Medicine. 18:107-114
Aim: The aim of this study was to explore the effects of ABCB1 and SLCO1B1 gene polymorphisms and the methotrexate (MTX) treatment response in patients with low-risk gestational trophoblastic neoplasia (GTN). Materials & methods: Low-risk GTN patient
Autor:
Kalet León, Danay Saavedra, Armando Caballero, Jorge Alain Caballero, Zaima Mazorra, Carlos Figueredo, Ana Laura Añe-Kouri, Naivy Sánchez, Carlos Herrera, Lázaro Manuel Filgueira, Julio Betancourt Cervantes, Mayra Ramos, Geidy Lorenzo, Jorge Berrio, Meylan Cepeda, Orlando Adolfo Lovelle, Tania Crombet
Publikováno v:
Immunotherapy
In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious
Autor:
Ross Salvaris, Stephen Opat
Publikováno v:
Future Oncology. 17:371-387
In the last decade, the treatment of chronic lymphocytic leukemia (CLL) has shifted away from chemoimmunotherapy toward targeted novel agents such as small molecule inhibitors and antibodies. Here, we give an overview of the pharmacology of venetocla
Publikováno v:
Future Microbiology. 16:27-36
Rezafungin is a novel echinocandin with exceptional stability and solubility and a uniquely long half-life allowing for front-loaded drug exposure with once-weekly dosing. Rezafungin has been shown comparable to other echinocandins, with activity aga
Autor:
Huiqiang Huang, Constantine S. Tam, Steven Le Gouill, Michael Wang, Stephen D. Smith, Alfredo Romano, Jane Huang, Eric Holmgren, Marco Ladetto, Martin Dreyling, William Novotny, Melannie Co
Publikováno v:
Future Oncology. 17:255-262
Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem
Autor:
Franco Nolè, Rodolfo Montironi, Matteo Santoni, Veronica Mollica, Antonio Lopez-Beltran, Alessia Cimadamore, Nicola Battelli, Liang Cheng, Francesco Massari, Gaetano Aurilio
Publikováno v:
Immunotherapy. 12:1257-1268
Immune checkpoint inhibitors have radically changed the treatment approach to metastatic renal cell carcinoma (mRCC). In the present article, we reported and discussed the available data with immunocombinations in mRCC, offering new perspectives in t